Case study on a deep excavation in soft ground by centrifuge model tests

This paper provides a case study on the deepest excavation carried out so far in the construction of the metro network in Shanghai, which typically features soft ground. The excavation is 38 m deep with retaining walls 65 m deep braced by 9 levels of concrete props. To obtain a quick and rough prediction, two centrifuge model tests were conducted, in which one is for the 'standard' section with green field surrounding and the other with an adjacent piled building. The tests were carried out in a run-stop-excavation-run style, in which excavation was conducted manually. By analyzing the lateral wall displacement, ground deformation, bending moment and earth pressure, the test results are shown to be reasonably convincing and the design and construction were validated. Such industry orientated centrifuge modeling was shown to be useful in understanding the performance of geotechnical processes, especially when engineers lack relevant field experience. © 2010 Taylor & Francis Group, London.

Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.

AIMS: Regenerative medicine is an emerging field with the potential to provide widespread improvement in healthcare and patient wellbeing via the delivery of therapies that can restore, regenerate or repair damaged tissue. As an industry, it could significantly contribute to economic growth if products are successfully commercialized. However, to date, relatively few products have reached the market owing to a variety of barriers, including a lack of funding and regulatory hurdles. The present study analyzes industry perceptions of the barriers to commercialization that currently impede the success of the regenerative medicine industry in the UK. MATERIALS & METHODS: The analysis is based on 20 interviews with leading industrialists in the field. RESULTS: The study revealed that scientific research in regenerative medicine is thriving in the UK. Unfortunately, lack of access to capital, regulatory hurdles, lack of clinical evidence leading to problems with reimbursement, as well as the culture of the NHS do not provide a good environment for the commercialization of regenerative medicine products. CONCLUSION: Policy interventions, including increased translational government funding, a change in NHS and NICE organization and policies, and regulatory clarity, would likely improve the general outcomes for the regenerative medicine industry in the UK.

Innovation processes within the healthcare industry: Determining critical success factors aligned to product strategies

The impact of differing product strategies on product innovation processes pursued by healthcare firms is discussed. The critical success factors aligned to product strategies are presented. A definite split between pioneering product strategies and late entrant product strategies is also recognised.